Gleevec is the trade name of Imatinib Mesylate Tablets, whose active ingredient Imatinib Mesylate can inhibit tyrosine kinase at the cellular level both in vitro and in vivo, with the following effects: 1. It can selectively inhibit the proliferation and induce apoptosis of fresh cells from patients with Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia; 2. It can inhibit the proliferation and induce apoptosis of gastrointestinal mesenchymal tumor cells . This drug is a prescription drug and must be used rationally under the guidance of a doctor. If you are using other drugs, to prevent drug interaction and affect the treatment, please consult your doctor in charge before use.